SNGX News and Press, Soligenix Inc. From 01/12/22

New York, New York--(Newsfile Corp. - January 12, 2022) - PCG Digital -- Soligenix, Inc. (NASDAQ: SNGX), a US-based late-stage biopharmaceutical company, issued a corporate update this week with good news for their shareholders. Despite supply-chain delays in receiving the active pharmaceutica...

Soligenix Corporate Update Letter - Key Highlights and Upcoming Catalysts PR Newswire PRINCETON, N.J. , Jan. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and ...

Soligenix to Present at Upcoming Investor Conferences PR Newswire PRINCETON, N.J. , Jan. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing produ...

Dusquetide Demonstrates Positive Anti-tumor Efficacy in Multiple Nonclinical Animal Studies Complementary treatment with chemotherapy, radiation and targeted therapy supports development as potential anti-cancer agent PR Newswire PRINCETON, N.J. , Jan. 4, 2022 ...

Soligenix (NASDAQ:SNGX) announces 100% protection of non-human primates (NHPs) against lethal Sudan ebolavirus challenge using a bivalent, thermostabilized vaccine formulated in a single vial, reconstituted only with water immediately prior to use. This is part of an ongoing collaboration wit...

Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine Thermostabilized single vial vaccine targeting Sudan and Marburg filoviruses protects 100% of non-human primates against lethal Sudan ebolavirus challenge PR Newswire PRIN...

New York, New York--(Newsfile Corp. - November 30, 2021) - PCG Digital -- Proof of concept in the biopharmaceutical sector is a process. Efficacy tests are performed, results are recorded from each round of clinical trials, and formulation changes are made if necessary. Each iteration moves th...

Soligenix (NASDAQ:SNGX): Q3 GAAP EPS of -$0.09 beats by $0.03. Revenue of $0.2M (-66.7% Y/Y) misses by $0.3M. Press Release For further details see: Soligenix EPS beats by $0.03, misses on revenue

Soligenix Announces Recent Accomplishments And Third Quarter 2021 Financial Results PR Newswire PRINCETON, N.J. , Nov. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing...

Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom PR Newswire PRINCETON, N.J. , Nov. 8, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical com...